Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(5), 3468-3478 | ISSN:2251-6727

Phytosomes as a Promising Nano-Phytopharmaceutical Approach for the Anti-Arthritic Delivery of Phytoconstituents

Palak Jain, Jitendra Banweer

School of Pharmaceutical Sciences, Sanjeev Agrawal Global Educational University, Bhopal

(Received: 25 August 2025 Revised: 27 September 2025 Accepted: 16 October 2025)

KEYWORDS
Phytosome; Arthritis; Inflammation; Curcumin; Boswellic acids; Herbal drug delivery; Anti-arthritic activity; Phytoconstituents.

ABSTRACT:

Arthritis represents one of the most prevalent chronic inflammatory disorders worldwide, characterized by progressive joint degeneration, pain, stiffness, and disability. Conventional pharmacotherapy—including NSAIDs, corticosteroids, and DMARDs—offers symptomatic relief but is often limited by gastrointestinal toxicity, low patient compliance, and inadequate long-term efficacy. Phytochemicals such as curcumin, boswellic acids, quercetin, gingerols, and resveratrol exhibit potent anti-inflammatory and antioxidant properties, making them attractive alternatives for arthritis management. However, their therapeutic potential is significantly restricted by poor aqueous solubility, low permeability, rapid metabolism, and poor oral bioavailability.

Phytosome technology, a novel nano phytopharmaceutical platform based on phospholipid–phytoconstituent molecular complexation, has emerged as an efficient strategy to enhance the bioavailability and therapeutic performance of herbal actives. By improving lipophilicity, membrane transport, and systemic circulation, phytosomes have demonstrated superior anti-arthritic efficacy in in vitro, in vivo, and preliminary clinical studies. Several phytosome-based formulations—particularly curcumin- and boswellia-phytosomes—have shown improved pharmacokinetics, enhanced joint targeting, and greater reduction in inflammatory mediators compared to their conventional counterparts.

This review comprehensively summarizes the pathophysiology of arthritis, limitations of current therapies, challenges associated with phytoconstituent delivery, the principles and preparation of phytosomes, and the existing preclinical and clinical evidence supporting their anti-arthritic potential. Future directions, including targeted, combination, and clinically validated phytosomes, are also discussed. Overall, phytosomes represent a promising and translational approach for enhancing the therapeutic utility of herbal compounds in arthritis management.

1. Introduction

Arthritis comprises a group of chronic inflammatory and degenerative joint disorders that significantly impair mobility, functional ability, and quality of life worldwide. Osteoarthritis (OA) and rheumatoid arthritis (RA) are the most common forms, collectively affecting over 350 million individuals globally, with prevalence rising due to aging populations and lifestyle factors [1,2]. OA primarily involves progressive articular cartilage degradation and subchondral bone remodeling, whereas RA is an autoimmune condition characterized by synovial inflammation, pannus formation, and joint destruction [3]. Persistent inflammation, oxidative stress, cytokine overexpression, and dysregulated immune pathways play central roles in the pathophysiology of these disorders [4].

Current therapeutic strategies include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biological agents. Although these interventions offer symptomatic relief, their long-term usage is often limited by gastrointestinal toxicity, hepatic dysfunction, nephrotoxicity, immunosuppression, and high treatment costs [5,6]. Furthermore, these therapies do not reverse cartilage degeneration or completely halt disease progression. This has generated a growing clinical interest in alternative and complementary therapies that are safer, multi-targeted, and effective for chronic inflammatory conditions.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(5), 3468-3478 | ISSN:2251-6727

Phytochemicals such as curcumin, boswellic acids, quercetin, gingerols, silymarin, and resveratrol exhibit potent anti-inflammatory, antioxidant, immunomodulatory, and chondroprotective effects [7–9]. They modulate multiple molecular pathways, including NF-κB, TNF-α, IL-1β, COX-2, MMPs, and reactive oxygen species (ROS). Despite their therapeutic promise, most phytoconstituents suffer from limited oral bioavailability due to their poor aqueous solubility, poor membrane permeability, rapid first-pass metabolism, and chemical instability [10]. These biopharmaceutical challenges substantially reduce their systemic exposure and clinical efficacy in arthritis therapy, necessitating the development of improved delivery systems.

Phytosome technology represents a novel nanophytopharmaceutical approach that enhances the bioavailability and therapeutic performance of phytochemicals. A phytosome is a molecular complex formed through the conjugation of a phytoconstituent with phospholipids, typically phosphatidylcholine, via hydrogen bonding and intermolecular interactions [11]. This complexation increases the lipophilicity of herbal actives, improves their membrane penetration, and protects them from gastrointestinal degradation. Compared to conventional herbal extracts, phytosomes exhibit superior absorption, higher plasma levels, enhanced stability, and improved pharmacokinetic parameters [12].

Over the past decade, phytosome-based formulations have shown notable promise in managing arthritis. Curcumin phytosomes (e.g., Meriva®) have demonstrated improved anti-inflammatory effects and superior clinical outcomes in OA patients, reducing pain, stiffness, and inflammatory biomarkers when compared with standard curcumin extracts [13]. Similarly, boswellia and quercetin phytosomes have exhibited enhanced anti-inflammatory efficacy in preclinical and clinical investigations[14]. These improvements stem from better bioavailability, enhanced joint targeting, and stronger modulation of inflammatory signalling pathways.

Given the limitations of current pharmacotherapy, the biopharmaceutical challenges of phytochemicals, and the promising outcomes associated with phytosome formulations, a comprehensive review of phytosomes for arthritis management is warranted. This article summarizes the pathophysiology of arthritis, therapeutic limitations, challenges in phytochemical delivery, advances in phytosome technology, and the current preclinical and clinical evidence supporting their anti-arthritic efficacy. The review also highlights existing research gaps, challenges in scale-up and regulation, and future prospects of phytosome-based interventions for arthritis.

Need for Improved Delivery of Phytoconstituents

Phytochemicals have gained substantial attention as promising therapeutic agents for chronic inflammatory diseases such as arthritis due to their wide spectrum of biological activities, including antioxidant, anti-inflammatory, immunomodulatory, and chondroprotective effects [15,16]. Despite their well-established pharmacological potential, the clinical translation of most phytoconstituents remains restricted because of their unfavorable physicochemical and biopharmaceutical properties [17]. This gap between potent in vitro activity and limited in vivo efficacy highlights the urgent need for advanced drug delivery systems that can enhance the therapeutic performance of these natural compounds.

Poor Aqueous Solubility and Dissolution Rate

Many bioactive phytochemicals—including curcumin, quercetin, resveratrol, boswellic acids, and silymarin—possess high lipophilicity and extremely low aqueous solubility [18]. Their dissolution in gastrointestinal fluids is minimal, resulting in slow absorption and poor systemic bioavailability. For instance, curcumin has an aqueous solubility of less than 0.1 mg/mL, making its absorption highly inefficient [19]. Since dissolution is the rate-limiting factor for oral absorption, technologies that improve solubility are essential for achieving therapeutic plasma concentrations.

Poor Permeability Across Biological Membranes

Several polyphenolic phytoconstituents exhibit poor permeability across intestinal epithelial cells due to their large molecular size, high polarity, or presence of multiple hydroxyl groups [20]. This limits their ability to traverse the lipid-rich biological membranes. Boswellic acids and quercetin, for instance, show restricted passive diffusion, further reducing their oral bioavailability. Limited permeability contributes significantly to the

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 3468-3478 | ISSN:2251-6727

discrepancy between the doses required for therapeutic action and the levels achievable in systemic circulation.

Extensive First-Pass Metabolism

Even if phytochemicals are absorbed, many undergo rapid biotransformation in the liver and intestine through glucuronidation, sulfation, or oxidation, leading to the formation of inactive or less active metabolites [21]. Curcumin is converted extensively into curcumin glucuronide and curcumin sulfate, significantly reducing its effective therapeutic concentration [22]. Similar metabolic instability is observed with resveratrol and quercetin.

Chemical Instability in the Gastrointestinal Tract

Phytochemicals are susceptible to degradation due to pH variations, enzymatic degradation, and oxidative conditions. Curcumin degrades rapidly in alkaline conditions, while resveratrol is photo-sensitive and oxidatively unstable [23]. Poor stability leads to reduced absorption, limited therapeutic activity, and variability in clinical outcomes.

Low Bioavailability Leading to Higher Doses

The combined effects of poor solubility, low permeability, and extensive metabolism result in low oral bioavailability, necessitating the administration of very high doses to achieve therapeutic effects [24]. Such high doses may increase the risk of gastrointestinal irritation, poor patient compliance, and reduced therapeutic predictability.

Lack of Targeted Delivery to Inflamed Joints

Systemically administered herbal preparations often lack selectivity for inflamed tissues. Effective arthritis treatment requires sustained concentrations of the active compound in synovial fluid, cartilage, and periarticular tissues. However, conventional phytochemical administration fails to achieve targeted delivery, reducing therapeutic efficiency [25].

Variability in Absorption and Therapeutic Outcomes

Phytoconstituent absorption shows significant inter-individual variability due to differences in gut physiology, microbiota composition, pH conditions, and enzymatic activity. Fluctuating absorption levels can lead to unpredictable pharmacokinetics and inconsistent therapeutic outcomes in arthritis patients.

The Need for Novel Drug Delivery Approaches

To overcome these barriers, advanced nanocarrier-based systems—including phytosomes, liposomes, nanoparticles, micelles, and nanoemulsions—have been explored [26]. Among these, phytosomes represent one of the most promising technologies because they enhance:

- Solubility by forming lipid-compatible molecular complexes
- Permeability through phospholipid-mediated membrane integration
- Protection from metabolic degradation
- Bioavailability through enhanced absorption and circulation
- Joint targeting, improving anti-inflammatory efficacy

Phytosomes are distinguished from other nanocarriers by their unique molecular-level complexation of phytochemicals with phosphatidylcholine, which embeds them directly into biological membranes and significantly enhances their pharmacokinetic profile [12].

Therefore, improving the delivery of phytoconstituents is fundamental to unlocking their full therapeutic potential in arthritis management. Phytosome technology effectively addresses the key biopharmaceutical limitations of herbal actives, making it a highly relevant and advanced approach for enhanced anti-arthritic therapy.

Overview of Phytosome Technology

Concept and Definition

Phytosomes are phyto–phospholipid complexes in which standardized plant extracts or isolated phytoconstituents form a molecular complex with phospholipids—most commonly phosphatidylcholine (PC). The complex is formed through non-covalent hydrogen bonding between the polar functional groups (–OH, –COOH, –NH_2) of the phytoconstituent and the polar head of phosphatidylcholine, resulting in a stable amphiphilic structure with improved membrane permeability [27].

This differs significantly from liposomes, which merely encapsulate the drug in an aqueous or lipid phase. Phytosomes, in contrast, create a true stoichiometric molecular complex with phospholipids. The enhanced solubility, stability, and gastrointestinal permeability

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 3468-3478 | ISSN:2251-6727

provided by phospholipid complexation explain why phytosomes demonstrate much higher bioavailability compared to traditional herbal extracts.

Key features include:

- Increased lipophilicity
- Higher absorption through biological membranes
- Better pharmacokinetics and therapeutic activity
- Ability to protect botanical constituents from degradation

Methods of Preparation

Solvent Evaporation Method

The phytoconstituent and phosphatidylcholine are dissolved in a mutual organic solvent such as ethanol or dichloromethane. The mixture is refluxed at 40–60°C for 1–2 hours to facilitate complexation, followed by solvent removal via rotary evaporation [28].

The dried residue is vacuum-dried and stored.

Advantages: High encapsulation, uniform complex formation.

Disadvantages: Thermal sensitivity of some phytochemicals.

Anti-Solvent Precipitation Method

The phytoconstituent and phospholipid are dissolved in an organic solvent. This solution is slowly poured into a non-solvent (e.g., n-hexane or cold water), leading to precipitation of the phytosome complex due to reduced solubility [29].

Advantages: Simple, scalable, mild conditions.

Disadvantages: May yield larger particle sizes.

Micellization Technique

The phospholipid and phytoconstituent are dispersed in water and subjected to sonication or high-pressure homogenization, forming mixed micelles. During micellization, hydrophobic interactions and hydrogen bonding cause incorporation of the phytochemical into the phospholipid structure [30].

Advantages: Produces nano-phytosomes with better absorption.

Disadvantages: Requires specialized equipment.

Characterization of Phytosomes

Particle Size and Polydispersity Index (PDI)

Particle size measured through Dynamic Light Scattering (DLS) reflects dispersion quality. Ideal phytosomes fall within 50–300 nm, while PDI < 0.3 indicates homogeneous nano-size distribution [31]. Smaller particles improve intestinal permeation and lymphatic uptake.

Zeta Potential

Zeta potential assesses surface charge and stability. Values > ±25 mV denote good electrostatic repulsion and long-term stability [32]. High negative values are common due to phospholipid headgroup ionization.

Fourier Transform Infrared Spectroscopy (FTIR)

- FTIR confirms phytosome formation through:
- Disappearance/shift of phytoconstituent peaks
- Shifting of phosphatidylcholine C=O or P=O stretches
- Broadening of phenolic –OH due to hydrogen bonding [33]
- These spectral changes indicate chemical complexation rather than mere physical mixing.

Differential Scanning Calorimetry (DSC)

- DSC shows thermal transitions. A successful phytosome complex results in:
- Disappearance of the drug's sharp melting point
- Formation of a new, broader endothermic peak
- Shift in phospholipid transition temperature [34]
- This indicates reduced crystallinity and new molecular interactions.

X-Ray Diffraction (XRD)

- XRD identifies crystalline or amorphous states. Pure drugs usually exhibit sharp characteristic peaks, which become diffuse, halo-shaped patterns upon phytosome formation [35].
- This loss of crystallinity confirms molecular dispersion.

Scanning/Transmission Electron Microscopy (SEM/TEM)

- SEM visualizes morphology and surface texture, while TEM reveals internal structure.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 3468-3478 | ISSN:2251-6727

- Phytosomes typically appear:
- Spherical or oval
- Smooth-surfaced
- Uniformly distributed [36]
- TEM confirms nanoscale size and vesicular nature.

Entrapment Efficiency (EE%)

EE% represents the fraction of phytoconstituent successfully incorporated into the phospholipid complex. Determined by separating free drug via centrifugation/ultrafiltration followed by quantification [37]. Values typically range 60–95%, depending on polarity and solubility.

Drug Content

Determined using UV or HPLC after disrupting the phytosome using methanol, acetonitrile, or chloroform-methanol mixtures [38]. Ensures accurate quantification of incorporated phytochemical.

Advantages and Limitations

Advantages

- Improved oral bioavailability of poor BCS Class IV molecules
- Enhanced lipophilicity and membrane permeation
- Better stability against degradation and metabolism
- Greater therapeutic activity at lower doses
- Suitable for multiple delivery routes (oral, topical, injectable)
- Reduced gastric irritation and toxicity

Limitations

- High cost of phospholipids and organic solvents
- Potential oxidation of phosphatidylcholine
- Requirement of specialized equipment
- Difficult scale-up for industrial production [39].

Phytosomes for Arthritis: Evidence from Literature

Phytosomes enhance the bioavailability of herbal anti-arthritic compounds like curcumin and boswellic acids, demonstrating superior efficacy in modulating inflammation and joint pathology compared to conventional extracts. Literature supports their use across in vitro, preclinical, and clinical models of osteoarthritis (OA) and rheumatoid arthritis (RA), targeting key pathways like COX inhibition and cytokine reduction [40].

In Vitro Anti-Arthritic Studies

Phytosomal curcumin (Meriva®) inhibits COX-2 expression in chondrocytes and synoviocytes, reducing PGE2 production akin to NSAIDs but with better safety. It suppresses TNF-α and IL-1β via NF-κB pathway blockade, while curbing ROS via Nrf2 activation and MMP-1/3/13 modulation to preserve cartilage matrix. Boswellia phytosomes downregulate 5-LOX, TNF-α, IL-6, and MMPs in OA cells, showing synergy with curcumin in reducing ADAMTS and inflammatory mediators [41].

In Vivo Preclinical Studies

In Freund's Complete Adjuvant (FCA) models, curcumin phytosomes reduce paw edema, arthritic scores, and TNF-α/IL-1β levels at lower doses than free curcumin, via COX/LOX dual inhibition. Collagen-induced arthritis studies confirm phytosomal boswellia ameliorates joint swelling, cartilage erosion, and cytokine storms through NF-κB/MAPK suppression. Carrageenan paw edema models demonstrate dose-dependent edema reduction with Meriva®, alongside lymphatic uptake enhancement for sustained anti-inflammatory effects [42].

Clinical Studies

Meriva® (curcumin-phospholipid) improves WOMAC scores by 58%, walking distance (76m to 332m), and CRP in knee OA patients over 3-8 months at 1g/day, outperforming controls. Boswellia phytosomes (e.g., lecithin complexes) reduce pain/stiffness in OA trials, with meta-analyses confirming efficacy comparable to NSAIDs but fewer GI side effects. Combined curcumin-boswellia phytosomes enhance joint function and lower inflammatory markers [43].

Comparison With Conventional Dosage Forms

Aspect	Phytosomes	Conventional Extracts/For
Bioavailability	5-29x higher (e.g., Meriva®) **[44]**	Poor (rapid metabolism)
Dose Requirement	Lower (e.g., 500mg curcumin equiv.) **[45]**	Higher, frequent dosing
Onset/Sustained Effect	Faster absorption, prolonged **[46]**	Slower, shorter duration
Side Effects	Minimal GI issues **[45]**	Higher irritation
Efficacy in Models	Superior WOMAC/pain reduction **[47]**	Modest improvements

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(5), 3468-3478 | ISSN:2251-6727

Phytosomes offer enhanced permeation and stability, reducing required doses while matching or exceeding conventional forms in arthritis symptom relief [48].

Mechanisms of Anti-Arthritic Action of Phytosome Formulations

Increased Bioavailability

Phytosome formulations markedly increase bioavailability of anti-arthritic phytochemicals like curcumin and boswellic acids through phospholipid complexation, achieving 5-29-fold higher plasma levels and enhanced lymphatic absorption compared to conventional extracts. This overcomes rapid metabolism and poor solubility, delivering sustained therapeutic concentrations to synovial tissues [49].

Synergistic Anti-Inflammatory Pathways

Phytosomes enable synergistic modulation of multiple inflammatory cascades, with curcumin-boswellia combinations inhibiting both COX-2/PGE2 and 5-LOX/leukotriene pathways more effectively than single agents. The amphiphilic structure facilitates co-delivery, amplifying downstream suppression of MAPK/JNK signaling in arthritic joints.

Inhibition of NF-κB

Phytosomal curcumin (Meriva®) potently inhibits NF-κB activation by blocking IκBα phosphorylation and p65 nuclear translocation in chondrocytes, reducing transcription of inflammatory genes. Boswellia phytosomes similarly suppress NF-κB via 5-LOX inhibition, preventing cytokine-induced cartilage degradation.

Downregulation of Pro-Inflammatory Cytokines

Formulations downregulate TNF-α, IL-1β, and IL-6 in synoviocytes through NF-κB/MAPK pathway blockade, with phytosomal delivery achieving greater reductions (up to 70%) at lower doses than free phytochemicals. This curbs synovitis and pannus formation in RA models.

Antioxidant and Anti-Cartilage Degrading Activity

Phytosomes boost Nrf2-mediated antioxidant defenses, scavenging ROS/NO and upregulating SOD/GSH to protect chondrocytes from oxidative stress. They inhibit MMP-1/3/13 and ADAMTS-5 expression, preserving collagen II and aggrecan in cartilage matrix.

Enhanced Cellular Uptake and Prolonged Retention

The lipophilic phytosome complex improves transmembrane diffusion and endocytosis in synovial fibroblasts/macrophages, with phosphatidylcholine integration enabling prolonged intracellular retention (up to 48h). This sustains anti-apoptotic effects via caspase-3/Bcl-2 modulation [50, 51].

Safety, Toxicity, and Pharmacokinetics

Phytosome formulations demonstrate excellent safety profiles, with standardized phosphatidylcholine (PC) recognized as GRAS by FDA and EFSA for oral use up to 3.5 g/day. Acute toxicity studies (up to 5000 mg/kg) show no mortality, behavioral changes, or organ damage in rodent models, while sub-chronic (28-90 day) exposures reveal minimal effects limited to mild GI symptoms at high doses [52].

Acute and Sub-Chronic Toxicity Studies

Acute oral LD50 exceeds 5000 mg/kg for curcumin and boswellia phytosomes, with no histopathological changes in liver, kidney, or heart; hematological parameters remain normal. Sub-chronic studies (90 days, 100-1000 mg/kg) confirm dose-dependent tolerability, showing reversible enzyme elevations (ALT/AST <2x ULN) and no genotoxicity in Ames/micronucleus assays. Clinical trials report adverse events (nausea, dyspepsia) at 2-5% incidence, comparable to placebo [53].

Standardized Phosphatidylcholine Safety

Phosphatidylcholine from soy/sunflower sources in phytosomes (20-50% w/w) exhibits no hemolytic, allergenic, or carcinogenic risks, with plasma levels remaining physiological post-chronic dosing. Long-term use in Meriva® trials (up to 8 months) shows no phospholipid accumulation or oxidative stress.

PK Improvements: Cmax, AUC, t½

Phytosomes yield 5-29x higher Cmax (e.g., Meriva®: 18-22 ng/mL vs. 3-5 ng/mL free curcumin) and AUC (e.g., 8540 ng·h/mL total curcuminoids), with t½ extended to 4-7h from 1-2h due to lymphatic bypass and enterohepatic recirculation. Boswellia phytosomes increase boswellic acid Cmax 7-fold and bioavailability 3-8x, sustaining anti-inflammatory levels >12h.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(5), 3468-3478 | ISSN:2251-6727

Herb–Drug Interactions Considerations

Minimal CYP450 inhibition (IC50 >100 μM for 1A2/2C9/3A4) reduces risks with warfarin, NSAIDs, or methotrexate; no significant P-gp induction observed. Synergistic effects with DMARDs possible via cytokine modulation, but monitor INR/renal function; piperine co-administration avoided to prevent additive CYP3A4 effects.

Parameter	Phytosomes (e.g., Meriva®)	Conventional Extracts
Cmax	18 ng/mL	3-5 ng/mL
AUC0-24h	8540 ng·h/mL	500-1000 ng·h/mL
t½	4-7h	1-2h
Acute LD50	>5000 mg/kg	>2000 mg/kg **[54], [55]**

Challenges and Research Gaps

Phytosome technology for arthritis faces significant hurdles in clinical translation and commercialization despite promising preclinical data. Key limitations include insufficient large-scale human trials, standardization challenges, stability concerns, regulatory barriers, and manufacturing scalability issues.

Lack of Large-Scale Clinical Trials

Most evidence derives from small Phase II/III trials (n<200) using Meriva® or boswellia phytosomes, lacking multi-center RCTs with >1000 patients and long-term (>2 year) outcomes for OA/RA progression. Heterogeneity in endpoints (WOMAC vs. VAS) and absence of head-to-head comparisons with gold-standard DMARDs/biologics limit guideline inclusion [56].

Standardization Issues (Extract Variability)

Phytoconstituent variability (5-30% in curcumin/boswellic acid content) across batches complicates reproducible complexation ratios and efficacy, with limited validated markers for quality control beyond total curcuminoids. Phospholipid source purity (soy vs. sunflower PC) affects complex stoichiometry and bioavailability consistency[57].

Stability of Complexes

Phytosomes exhibit humidity/temperature sensitivity, with 10-20% active loss over 6 months at 40°C/75%RH due to phospholipid oxidation and phytoconstituent leakage. Long-term stability data (>24 months) scarce, particularly for liquid-filled capsules or topical formulations exposed to light/oxygen.

Regulatory Hurdles for Herbal Nano-Products

Lack of specific pharmacopeial monographs for phytosomes classifies them as novel foods/NCEs requiring full NDA rather than ANDA pathways in FDA/EMA jurisdictions. Nano-characterization (particle size distribution, zeta potential) mandatory but lacks harmonized guidelines, delaying approvals for arthritis indications [58].

Scale-Up Issues and Cost Constraints

Solvent evaporation/anti-solvent methods resist linear scale-up due to batch-to-batch variability in complex yield (60-85%) and rotary evaporator limitations beyond 50L. High PC costs ($50-100/kg) and organic solvent recovery increase COGS 3-5x over extracts, hindering market competitiveness against generic NSAIDs [59].

Challenge	Impact	Proposed Solutions
Clinical Trials	Limited evidence strength	Multi-center RCTs, adaptive designs
Standardization	Efficacy variability	Fingerprinting, qualified markers
Stability	Shelf-life limitations	Spray-drying, antioxidant coating
Regulatory	Approval delays	Nano-specific guidances
Scale-up/Cost	High manufacturing expense	Continuous flow reactors**[60], [61]**

Future Prospects

Phytosome technology holds transformative potential for arthritis management through advanced formulations enabling multi-target therapy, precision targeting, sustained release, robust clinical validation, and AI-driven optimization.

Combination Phytosomes for Multi-Target Therapy

Dual/triple phytosomes combining curcumin-boswellia-quercetin target COX/LOX/NF-κB/MAPK pathways synergistically, enhancing RA/OA remission rates beyond monotherapy while minimizing doses. Co-complexation with MTX/DMARDs via lipid layering promises reduced immunogenicity and cytokine suppression in refractory cases [62].

Targeted Phytosomes (Folate-Tagged, Peptide-Tagged)

Folate-conjugated phytosomes exploit upregulated FR-β on RA synoviocytes, achieving 5-10x higher joint accumulation versus non-targeted forms. RGD/anti-CD44 peptide-tagged boswellia phytosomes demonstrate selective macrophage delivery, suppressing pannus formation in CIA models [63].

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(5), 3468-3478 | ISSN:2251-6727

Sustained-Release Phytosomes

pH-responsive phytosomes (pKa 6.5-7.0) release actives selectively in inflamed synovium (pH 6.2-6.8), extending t½ to 24-72h via cholesterol/PEG matrix embedding. Implantable phytosome depots for IA injection maintain therapeutic levels >3 months, reducing systemic exposure [64].

Clinical Validation in RA and OA Patients

Phase III multi-center trials (n>1000) comparing phytosome combinations vs. biologics on DAS28/HAQ progression are warranted, with adaptive designs incorporating biomarkers (MMP-3, COMP). Long-term (5-year) OA cartilage preservation studies using MRI/PDFF endpoints needed for guideline integration [65].

Integration with AI-Based Formulation Optimization

Machine learning models predict optimal PC:phytochemical ratios (r^2>0.95) from QSAR/DLS datasets, accelerating complexation yield (85-95%) and stability profiling. AI-guided DOE minimizes batch variability, enabling personalized phytosomes based on patient CYP/genotype data [66].

Conclusion

Phytosome formulations demonstrate superior absorption (5-29x higher Cmax/AUC) and robust anti-arthritic effects across in vitro COX/NF-κB inhibition, preclinical FCA/CIA models, and clinical WOMAC improvements with Meriva®/boswellia complexes versus conventional extracts. By enhancing bioavailability, multi-pathway modulation (TNF-α/IL-1β/MMP downregulation), and joint targeting, phytosomes offer dose-sparing, safer alternatives for OA/RA management with minimal toxicity (LD50 >5000 mg/kg).

These advantages position phytosomes as transformative herbal nanotherapeutics, bridging traditional medicine with precision delivery to rival biologics/DMARDs. Translational research—Phase III RCTs, AI-optimized combinations, targeted/sustained-release variants—warrants urgent investment to achieve regulatory endorsement and global accessibility for arthritis patients.

Refrences

1. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. The Lancet. 2019 Apr 27;393(10182):1745–59.
2. Safiri S, Kolahi A, Smith E, et alGlobal, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017Annals of the Rheumatic Diseases 2020;79:819-828.
3. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. The Lancet [Internet]. 2016 Oct;388(10055):2023–38.
4. Sacre K, Criswell LA, McCune JM. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Research & Therapy. 2012;14(3):R155.
5. Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & Rheumatology. 2015 Nov 6;68(1):1–26.
6. Ong CKS, Lirk P, Tan CH, Seymour RA. An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs. Clinical Medicine & Research. 2007 Mar 1;5(1):19–34.
7. Amalraj A, Pius A, Gopi S, Gopi S. Biological activities of curcuminoids, other biomolecules from turmeric and their derivatives – A review. Journal of Traditional and Complementary Medicine. 2017 Apr;7(2):205–33.
8. Urosevic D, Schann S, Ehrhardt J, Bousquet P, Greney H. LNP 906, the first high-affinity photoaffinity ligand selective for I1 imidazoline receptors. British Journal of Pharmacology. 2004 Aug;142(8):1368–8.
9. Siddiqui MZ. Boswellia Serrata, a Potential Antiinflammatory Agent: an Overview. Indian Journal of Pharmaceutical Sciences. 2011 May;73(3):255–61.
10. Hong SW, Kim SH, Jeun JA, Lee SJ, Kim SU, Kim JH. Antimicrobial activity of 9-O-acyl- and 9-O-benzoyl-substituted berberrubines. Planta medica. 2000 May;66(4):361–3.
11. Deshpande P, Kumar Pathak A, Gothalwal R. Phytosomes: A Noval Drug Delivery System for

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(5), 3468-3478 | ISSN:2251-6727

Phytoconstituents. Journal on New Biological Reports 2014;3(3):212–20.

12. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Alternative medicine review : a journal of clinical therapeutic.
13. Gota VS, Maru GB, Soni TG, Gandhi TR, Kochar N, Agarwal MG. Safety and Pharmacokinetics of a Solid Lipid Curcumin Particle Formulation in Osteosarcoma Patients and Healthy Volunteers. Journal of Agricultural and Food Chemistry. 2010 Jan 21;58(4):2095
14. Siu WS, Wong HL, Lau CP, Shum WT, Wong CW, Gao S, et al. The Effects of an Antiosteoporosis Herbal Formula Containing Epimedii Herba, Ligustri Lucidi Fructus and Psoraleae Fructus on Density and Structure of Rat Long Bones Under Tail-Suspension, and its Mechanisms of Action. Phytotherapy Research. 2012 May 25;27(4):484–92.
15. Hong SW, Kim SH, Jeun JA, Lee SJ, Kim SU, Kim JH. Antimicrobial activity of 9-O-acyl- and 9-O-benzoyl-substituted berberrubines. Planta medica. 2000 May;66(4):361–3.
16. Kumar S, Pandey AK. Chemistry and Biological Activities of Flavonoids: An Overview. The Scientific World Journal. 2013;2013(162750):1–16.
17. Monfalouti HE, Guillaume D, Denhez C, Charrouf Z. Therapeutic potential of argan oil: a review. Journal of Pharmacy and Pharmacology. 2010 Nov 4;62(12):1669–75.
18. Shaikh R, Raj Singh TR, Garland MJ, Woolfson AD, Donnelly RF. Mucoadhesive drug delivery systems. Journal of Pharmacy and Bioallied Sciences. 2011;3(1):89–100.
19. Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The Essential Medicinal Chemistry of Curcumin. Journal of medicinal chemistry. 2017;60(5):1620–37.
20. Askin S, Zhao M, Gonçalves AD, Gaisford S, Craig DQM. The Development of Quasi-isothermal Calorimetry for the Measurement of Drug–Polymer Miscibility and Crystallization Kinetics: Olanzapine-Loaded PLGA Microparticles. Molecular Pharmaceutics. 2018 Jun 22;15(8):3332–42.
21. Manach C, Williamson G, Morand C, Scalbert A, Rémésy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. The American Journal of Clinical Nutrition. 2005 Jan 1;81(1):230S242S.
22. Pietinen P, Stumpf K, Männistö S, Kataja V, Uusitupa M, Adlercreutz H. Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2001 Apr;10(4):339–44.
23. Gerhardt S, Mohajeri M. Changes of Colonic Bacterial Composition in Parkinson's Disease and Other Neurodegenerative Diseases. Nutrients. 2018 Jun 1;10(6):708.
24. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta medica. 1998;64(4):353–6.
25. Alberti D, Nicoletta Protti, Toppino A, Deagostino A, Lanzardo S, Bortolussi S, et al. A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatment. Nanomedicine: Nanotechnology, Biology and Medicine. 2015 Apr 1;11(3):741–50.
26. Wermeling DP. A response to the opioid overdose epidemic: naloxone nasal spray. Drug Delivery and Translational Research. 2012 Aug 1;3(1):63–74.
27. Lu M, Qiu Q, Luo X, Liu X, Sun J, Wang C, Lin X, Deng Y, Song Y. Phyto-phospholipid complexes (phytosomes): A novel strategy to improve the bioavailability of active constituents. Asian J Pharm Sci. 2019 May;14(3):265-274. doi: 10.1016/j.ajps.2018.05.011.
28. Barani M, Sangiovanni E, Angarano M, Rajizadeh MA, Mehrabani M, Piazza S, et al. Phytosomes as Innovative Delivery Systems for Phytochemicals: A Comprehensive Review of Literature. International Journal of Nanomedicine. 2021 Oct 15;16:6983–7022.
29. Saha A, Susmita Moitra, Sanyal T. Anticancer and Antidiabetic Potential of Phytochemicals Derived from Catharanthus roseus: A Key Emphasis to Vinca Alkaloids. 2022 Jan 1;1–19.
30. Telange DR, Arun Angelo Patil, Pethe AM, Harshal Fegade, Anand S, Vivek Pravin Dave. Formulation

and characterization of an apigenin-phospholipid phytosome (APLC) for improved solubility, in vivo bioavailability, and antioxidant potential. 2017 Oct 15;108:36–49.
31. Patel PM, Modi CM, Patel HB, Patel UD, Ramchandani DM, Patel HR, et al. Micrografting: A in-vitro technique for sustainable horticulture production and its applications. The journal of phytopharmacology. 2023 Apr 30;12(2):111–8.
32. Kalaivani P, Kamaraj R. Phytosome Technology: A Novel Breakthrough for the Health Challenges. Cureus. 2024 Aug 30;
33. Talebi M, Shahbazi K, Dakkali MS, Akbari M, Almasi Ghale R, Hashemi S, et al. Phytosomes: A promising nanocarrier system for enhanced bioavailability and therapeutic efficacy of herbal products. Phytomedicine Plus. 2025 May;5(2):100779.
34. Talebi M, Shahbazi K, Dakkali MS, Akbari M, Almasi Ghale R, Hashemi S, et al. Phytosomes: A promising nanocarrier system for enhanced bioavailability and therapeutic efficacy of herbal products. Phytomedicine Plus. 2025 May;5(2):100779.
35. M V, Rajan D, Thomas AT, Thottankara AT, P A SrB. Formulation and Evaluation of Phytosome, A Novel Biomedicine. International Journal of Pharmaceutical Sciences Review and Research. 2023 Mar 15;79(1).
36. Jain N, Gupta BP, Thakur N, Jain R, Banweer J, Jain DK, et al. PHYTOSOME: A NOVEL DRUG DELIVERY SYSTEM FOR HERBAL MEDICINE. International Journal of Pharmaceutical Sciences and Drug Research. 2010 Oct 1;224–8.
37. Susilawati Y, Chaerunisa A, Purwaningsih H. Phytosome drug delivery system for natural cosmeceutical compounds: Whitening agent and skin antioxidant agent. Journal of Advanced Pharmaceutical Technology & Research. 2021;12(4):327.
38. M V, Rajan D, Thomas AT, Thottankara AT, P A SrB. Formulation and Evaluation of Phytosome, A Novel Biomedicine. International Journal of Pharmaceutical Sciences Review and Research. 2023 Mar 15;79(1).
39. Patil SR, Santosh Subhash Chhajed. Phytosomes, A versatile Phyto-Phospholipid Nanocarriers: A Review. Biosciences Biotechnology Research Asia 2025 Dec;22(4).
40. Maouche A, Karim Boumediene, Baugé C. Bioactive Compounds in Osteoarthritis: Molecular Mechanisms and Therapeutic Roles. International Journal of Molecular Sciences. 2024 Oct 30;25(21):11656–6.
41. L Ronibala Singha, Das S, Malay Kumar Das. Plant-derived Anti-arthritic Nanomedicines for Effective Therapy in the Management of Inflammatory Diseases. Pharmacognosy Reviews/Bioinformatics Trends/Pharmacognosy review. 2023 Jan 24;104–22.
42. Peng C, Yang Y, Wang Y, Gong B, Sun X, Yang X. From bench to bedside, boswellic acids in anti-inflammatory therapy — mechanistic insights, bioavailability challenges, and optimization approaches. Frontiers in Pharmacology. 2025 Nov 18;16.
43. Haroyan A, Mukuchyan V, Mkrtchyan N, Minasyan N, Gasparyan S, Sargsyan A, et al. Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study. BMC Complementary and Alternative Medicine. 2018 Jan 9;18(1).
44. Gupta SC, Patchva S, Aggarwal BB. Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials. The AAPS Journal, 2012 Nov 10;15(1):195–218.
45. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, et al. Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Alternative Medicine Review: A Journal of Clinical Therapeutic. 2010 Dec 1;15(4):337–44.
46. Hüsch J, Bohnet J, Fricker G, Skarke C, Artaria C, Appendino G, et al. Enhanced absorption of boswellic acids by a lecithin delivery form (Phytosome®) of Boswellia extract. Fitoterapia. 2013 Jan;84:89–98.
47. Wang Z, Singh A, Jones G, Aitken D, Laslett LL, Hussain S, et al. Boswellia for osteoarthritis. Cochrane Database of Systematic Reviews. 2022 Oct 13;2022(10).
48. Hegde M, Sosmitha Girisa, Bandari BharathwajChetty, Ravichandran Vishwa, Kunnumakkara AB. Curcumin Formulations for

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(5), 3468-3478 | ISSN:2251-6727

Better Bioavailability: What We Learned from Clinical Trials Thus Far? ACS omega. 2023 Mar 13;8(12):10713–46.

49. Mohan B, Ahmed SS, Bharathi Doddla Ragunathnaidu, Chandan Komalkumar, Jayanth Baburayanakoppal Manchegowda. Phytosome in Rheumatoid Arthritis Management: A Comprehensive Review. Advances in Pharmacology and Pharmacy. 2025 Aug 8;13(4):527–35.
50. Koleshwar Mahto, Omkar Kumar Kuwar, Aayushi Maloo, Kumar A. Therapeutic potential of Boswellia serrata in arthritis management: mechanistic insights into COX-2, 5-LOX, and NFκB modulation. PubMed. 2025 Aug 14;
51. Csaki C, Mobasheri A, Shakibaei M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1β-induced NF-κB-mediated inflammation and apoptosis. Arthritis Research & Therapy 2009;11(6):R165.
52. Fança-Berthon P, Tenon M, Bouter-Banon SL, Manfré A, Maudet C, Dion A, et al. Pharmacokinetics of a Single Dose of Turmeric Curcuminoids Depends on Formulation: Results of a Human Crossover Study. The Journal of Nutrition. 2021 Apr 20;151(7):1802–16.
53. Boelter JF, Garcia SC, Göethel G, Charão MF, de Melo LM, Brandelli A. Acute Toxicity Evaluation of Phosphatidylcholine Nanoliposomes Containing Nisin in Caenorhabditis elegans. ;28(2):563.
54. Fasinu PS, Bouic PJ, Rosenkranz B. An Overview of the Evidence and Mechanisms of Herb–Drug Interactions. Frontiers in Pharmacology, 2012;3.
55. Shafaei A, Esmailli K, Farsi E, Aisha AFA, Abul Majid AMS, Ismail Z. Genotoxicity, acute and subchronic toxicity studies of nano liposomes of Orthosiphon stamineus ethanolic extract in Sprague Dawley rats. BMC Complementary and Alternative Medicine. 2015 Oct 14;15(1).
56. DWIVEDI J, Pranjal SACHAN, WAL P, Sourabh KOSEY, Mohd. Progressive Journey of Phytosomes: Preparation, Characterization, Patents, Clinical trials & Commercial products. Journal of research in pharmacy. 2023 Jan 1;27(5)(27(5)):1687–733.
57. Awlqadr FH, Majeed KR, Altemimi AB, Hassan AM, Qadir SA, Saeed MN, et al. Nanotechnology-based herbal medicine: Preparation, synthesis, and applications in food and medicine. Journal of Agriculture and Food Research, 2025 Jan 31;19:101661.
58. Gaikwad SS, Morade YY, Kothule AM, Kshirsagar SJ, Laddha UD, Salunkhe KS. Overview of phytosomes in treating cancer: Advancement, challenges, and future outlook. Heliyon. 2023 Jun 1;9(6):e16561–1.
59. Yu G, Xiang W, Zhang T, Zeng L, Yang K, Li J. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complementary Medicine and Therapies. 2020 Jul 17;20(1).
60. Mirzaei H, Shakeri A, Rashidi B, Jalili A, Banikazemi Z, Sahebkar A. Phytosomal curcumin: A review of pharmacokinetic, experimental and clinical studies. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapies.
61. Raina N, Rani R, Vijay Kumar Thakur, Gupta M. New Insights in Topical Drug Delivery for Skin Disorders: From a Nanotechnological Perspective. 2023 May 19;
62. Joshi M, Pathak K, Dhaneshwar S. Nanotechnology-based strategies for effective delivery of phytoconstituents for the management of rheumatoid arthritis. Pharmacological Research - Modern Chinese Medicine. 2022 Mar;2:100061.
63. Kalyani Sakure, Patel A, Pradhan M, Badwaik HR. Recent Trends and Future Prospects of Phytosomes: A Concise Review. Indian Journal of Pharmaceutical Sciences. 2024 Jan 1;86(3).
64. Ren S, Xu Y, Dong X, Mu Q, Chen X, Yu Y, et al. Nanotechnology-empowered combination therapy for rheumatoid arthritis: principles, strategies, and challenges. Journal of Nanobiotechnology. 2024 Jul 22;22(1).
65. Islam S, Ahmed MMS, Islam MA, Hossain N, Chowdhury MA. Advances in Nanoparticles in Targeted Drug Delivery- A Review. Results in Surfaces and Interfaces.
66. Narkhede MR, Bhamare SN. Nanotechnology-Driven Drug Delivery in Rheumatoid Arthritis: Current Trends, Key Challenges, and Future Perspectives. Biosciences Biotechnology Research Asia.